PanGIA Biotech, Inc. ("PanGIA Biotech" or "Company") announced that two research abstracts have been accepted for presentation at the American Association for Cancer Research ("AACR") Annual Meeting ...
Bottom Line: A machine learning model that analyzes patient demographics, electronic health record data, and routine blood test results predicted a patient’s risk of hepatocellular carcinoma (HCC), ...
Prostate cancer remains one of the most common diseases among men, yet current screening methods often lead to unnecessary ...
TOBY’s urine-based MCED test received FDA Breakthrough Device Designation. This is the first urine-based MCED platform ...
Using Real-World Data for Machine-Learning Algorithms to Predict the Treatment Response in Advanced Melanoma: A Pilot Study for Personalizing Cancer Care This study aims to investigate the impact of ...
Feasibility and Implementation of a Digital Health Intervention Electronic Patient-Reported Outcomes–Based Platform for Telemonitoring Patients With Breast Cancer Undergoing Chemotherapy Among the 76 ...
The United States Food and Drug Administration (FDA) issued guidance on its “Breakthrough Devices Program” in 2023. The ...
An exploration of how targeted nanoparticles and artificial intelligence algorithms combine to locate prostate cancer earlier ...
A Singaporean research team has developed CAN-Scan (short for Cancer Scan), a next-generation precision oncology platform designed to “scan” the molecular features of each patient’s cancer. Published ...
TOBY, Inc., a biotechnology company developing non-invasive cancer screening technologies, today announced that the U.S. Food ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results